Last edition
News about "NJ Bio "
NJ Bio, Aji Bio-Pharma Partner to Expand Access to AJICAP Platform
The collaboration between NJ Bio and Bio Pharma aims to accelerate development of next-generation antibody–drug conjugates through advanced site-specific conjugation technology.
NJ Bio | 01/04/2026 | By News Bureau
Cohance Lifesciences to Invest USD 10 Million to Expand cGMP Bioconjugation Capabilities in US
Cohance Lifesciences will invest USD 10 million to expand cGMP bioconjugation capabilities at its US-based subsidiary NJ Bio, strengthening its integrated Antibody-Drug Conjugate manufacturing capacity for global innovators.
NJ Bio | 13/08/2025 | By Mrinmoy Dey | 257
Suven Pharma to Acquire Stake in NJ Bio with Investment of USD 64.4 Million
NJ Bio has served 150+ customers, delivered over 500 projects in 5 years, and won the prestigious World ADC Awards for four consecutive years.
NJ Bio | 09/12/2024 | By Aishwarya | 414
NJ Bio Partners with Charles River to Accelerate ADC Development
The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs.
NJ Bio | 08/11/2024 | By Aishwarya | 269
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy